R&D News | pharmaphorum

News

Trump's NIH pick closer to role as court blocks budget cuts

NIH director nominee Jay Bhattacharya was quizzed closely on vaccines and budget cuts by the Senate HELP committee but seems odds on to take the job.

News

Enhertu extends survival in advanced gastric cancer

Data from a phase 3 trial of Enhertu in advanced HER2-positive gastric cancer could support wider use as a second-line therapy.

News

Antoine Papiernik, chairman and managing partner at Sofinnova Partners

Sofinnova raises €1.2bn to back 'up to 60' companies

Sofinnova has raised €1.2bn that it says could support 50 to 60 companies across biotech, medtech, industrial biotech, and digital medicine.

News

Takeda scores with polycythemia vera drug in phase 3 trial

A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.

News

Australia stands firm on 'no' to Alzheimer's drug Leqembi

Eisai and Biogen have been unable to persuade Australia's medicines regulator to approve their Alzheimer's therapy Leqembi with a narrower label.

News

GSK bows to Trump pressure and pauses diversity policies

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure from US President Trump.

Trump's NIH pick closer to role as court blocks budget cuts

Enhertu extends survival in advanced gastric cancer

Sofinnova raises €1.2bn to back 'up to 60' companies

Takeda scores with polycythemia vera drug in phase 3 trial

Australia stands firm on 'no' to Alzheimer's drug Leqembi

GSK bows to Trump pressure and pauses diversity policies

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks